Search results
17 wrz 2018 · Using a 3‐day mean fecal α 1 PI concentration of ≥4.0 μg/g appears to be a good test to screen (NPV > 90%) for PLE in dogs with CIE (the prevalence of histologic lesions typically seen with PLE is 20% of dogs with hypoalbuminemia and 20%‐30% of all dogs with CIE5, 9, 43, 45; Table Table2 2).43 However, although a value of ≥4.0 μg/g ...
25 lis 2013 · The Study Group recommends empirical application of immunosuppressive therapy for dogs with severe, persistent, or progressive glomerular disease in which there is evidence of an active immune-mediated pathogenesis on kidney biopsy and no identified contraindication to immunosuppressive therapy.
13 sie 2020 · Risk factors for the most common side effects, polyuria and polydipsia (PUPD), were evaluated using multivariable logistic regression modeling (P < 0.05). Results: During 2013, 28,472 study dogs received systemic glucocorticoids (6.2%, 95% CI 6.2–6.3).
and even fatal side effects could arise in the event of a catecholamine-producing tumour being sampled, such as pain, haemorrhage, and severe hypertensive crisis due to sudden release of catecholamine. Special stain (chromogranin A and synaptophysin) may help further in the diagnosis of pheochromocytoma when the histopathology is not definitive.
5 kwi 2024 · Take-Home Points. The mast cell tumor (MCT) prognostic panel is useful in guiding treatment recommendations for histologically low-grade MCTs with equivocal histologic features or clinical history concerning for aggressive behavior.
In addition, important performance criteria of diagnostic tests are briefly reviewed. Keywords: antibiotic-responsive enteropathy; dog; food-responsive enteropathy; inflammation; inflammatory bowel disease.
1 sie 2015 · Imatinib is a molecular targeted drug that inhibits the activity of some tyrosine kinases including KIT. •. Dysregulation of kinases due to their mutation is found in some tumours in dogs and cats. •. In particular, dysregulation of KIT is found in canine and feline mast cell tumours. •.
